Home LiteratureArticle Details
PMID: 18989113 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation.

Current opinion in neurology ·Vol. 21 ·No. 6 ·2008-12-00 ·Pages 683-7

Klunk WE, Mathis CA

Abstract

This review will focus on the coming proliferation of amyloid-beta imaging tracers and give an opinion on how the Alzheimer's disease field can develop a systematic means of evaluating which tracers are useful and how the useful tracers compare to each other. Several new tracers have been reported to be useful for human amyloid-beta imaging. The most recent of these are labeled with fluorine-18. Compared with the 20 min half-life of carbon-11 used in the most widely used tracer, Pittsburgh Compound-B, the 110 min half-life of fluorine-18 allows for wider utilization in research and clinical settings. It is likely that more than one fluorine-18-labeled tracer will come into common use. The use of preclinical and clinical 'bridging studies' to [C-11]Pittsburgh Compound-B could be a means to determine whether the sizable body of knowledge already gained in [C-11]Pittsburgh Compound-B studies can be applied to the understanding of these new tracers and to form a basis for the comparison among them. This approach could save resources and help sort out a potentially bewildering onslaught of new amyloid-beta imaging tracers.

MeSH Terms
Alzheimer Disease/diagnostic imaging,metabolism Amyloid beta-Peptides/metabolism Aniline Compounds Humans Positron-Emission Tomography Thiazoles
Chemicals
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole Amyloid beta-Peptides Aniline Compounds Thiazoles
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Klunk William E
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. [email protected]
Mathis Chester A
References (46)
46 references, click to expand
  1. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Neurology. 2007 Apr 10;68(15):1205-12 PMID: 17420404
  2. PET of brain amyloid and tau in mild cognitive impairment.
    N Engl J Med. 2006 Dec 21;355(25):2652-63 PMID: 17182990
  3. Imaging beta-amyloid burden in aging and dementia.
    Neurology. 2007 May 15;68(20):1718-25 PMID: 17502554
  4. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
    J Neurosci. 2007 Jun 6;27(23):6174-84 PMID: 17553989
  5. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease.
    Neurology. 2007 Jul 17;69(3):283-90 PMID: 17636066
  6. Abeta amyloid deposition in the language system and how the brain responds.
    Brain. 2007 Aug;130(Pt 8):2055-69 PMID: 17586869
  7. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
    Arch Neurol. 2007 Aug;64(8):1140-4 PMID: 17698704
  8. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
    Ann Neurol. 2007 Sep;62(3):229-34 PMID: 17683091
  9. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.
    J Neurosci. 2007 Oct 10;27(41):10957-68 PMID: 17928437
  10. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
    Brain. 2007 Nov;130(Pt 11):2837-44 PMID: 17928318
  11. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Neuroimage. 2008 Jan 15;39(2):619-33 PMID: 17962045
  12. In vivo amyloid imaging with PET in frontotemporal dementia.
    Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):100-6 PMID: 17846768
  13. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.
    Arch Neurol. 2008 Jan;65(1):113-20 PMID: 18195148
  14. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
    Lancet Neurol. 2008 Feb;7(2):129-35 PMID: 18191617
  15. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.
    Ann Neurol. 2008 Jan;63(1):112-8 PMID: 18023012
  16. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  17. Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP.
    Synapse. 2008 Jun;62(6):472-5 PMID: 18361444
  18. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.
    Ann Neurol. 2008 Mar;63(3):377-87 PMID: 18300294
  19. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.
    Arch Neurol. 2008 Apr;65(4):540-4 PMID: 18413480
  20. [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.
    Parkinsonism Relat Disord. 2008;14(4):345-7 PMID: 17855149
  21. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Brain. 2008 Jun;131(Pt 6):1630-45 PMID: 18339640
  22. PET imaging of amyloid deposition in patients with mild cognitive impairment.
    Neurobiol Aging. 2008 Oct;29(10):1456-65 PMID: 17499392
  23. Frequent amyloid deposition without significant cognitive impairment among the elderly.
    Arch Neurol. 2008 Nov;65(11):1509-17 PMID: 19001171
  24. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.
    Biochim Biophys Acta. 2000 Jul 26;1502(1):172-87 PMID: 10899442
  25. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease.
    J Neurosci. 2001 Dec 15;21(24):RC189 PMID: 11734604
  26. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.
    Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35 PMID: 11790632
  27. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain.
    J Med Chem. 2003 Jan 16;46(2):237-43 PMID: 12519062
  28. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  29. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.
    J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40 PMID: 1688924
  30. An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease.
    Experientia. 1992 Jan 15;48(1):8-10 PMID: 1371102
  31. Histochemistry and immunohistochemistry of Alzheimer's disease.
    Prog Histochem Cytochem. 1993;27(1):1-63 PMID: 7690493
  32. The immunopathology of Alzheimer's disease and some related disorders.
    Brain Pathol. 1993 Oct;3(4):333-47 PMID: 8293190
  33. Neuroimaging of vessel amyloid in Alzheimer's disease.
    Ann N Y Acad Sci. 1997 Sep 26;826:242-7 PMID: 9329695
  34. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
    Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):584-95 PMID: 15545326
  35. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.
    J Biol Chem. 2005 Jun 24;280(25):23599-604 PMID: 15855161
  36. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain.
    J Med Chem. 2005 Sep 22;48(19):5980-8 PMID: 16162001
  37. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    J Neurosci. 2005 Nov 16;25(46):10598-606 PMID: 16291932
  38. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Neurology. 2007 Feb 13;68(7):501-8 PMID: 17065593
  39. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
    Arch Neurol. 2007 Mar;64(3):431-4 PMID: 17353389
  40. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Neurology. 2007 May 8;68(19):1603-6 PMID: 17485647
  41. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
    Aging Cell. 2006 Feb;5(1):69-79 PMID: 16441845
  42. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  43. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment.
    Hum Mutat. 2006 Sep;27(9):888-96 PMID: 16917905
  44. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.
    Methods Enzymol. 2006;412:123-44 PMID: 17046656
  45. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):2856-66 PMID: 16854944
  46. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients.
    J Nucl Med. 2007 Apr;48(4):553-61 PMID: 17401091
Article Info
Journal
Current opinion in neurology
Abbr.
Curr Opin Neurol
ISSN
1350-7540
DOI
10.1097/WCO.0b013e3283168e1a
Email
[email protected]
Published
2008-12-00
Pages
683-7
Language
English
Region
England
NLM ID
9319162
PMCID
PMC2637561
Subset
IM
Grants
NIMH NIH HHS · K01 MH001976 · United States
NIA NIH HHS · R01 AG018402 · United States
NIMH NIH HHS · R01 MH070729 · United States
NIA NIH HHS · R37 AG025516-04 · United States
NIA NIH HHS · R37 AG025516 · United States
NIA NIH HHS · P01 AG025204-040001 · United States
NIA NIH HHS · K02 AG001039-05 · United States
NIA NIH HHS · P50 AG005133 · United States
NIA NIH HHS · RF1 AG025516 · United States
NIA NIH HHS · R01 AG020226-05 · United States
NIA NIH HHS · R01 AG020226 · United States
NIA NIH HHS · K02 AG001039 · United States
NIA NIH HHS · P50 AG005133-250021 · United States
NIA NIH HHS · P01 AG025204 · United States
External Links
PubMed source DOI: 10.1097/WCO.0b013e3283168e1a PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2